AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine

Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD

LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB)

Dear Shareholders,

I am writing to provide you with an update on our recent news of signing a definitive agreement to combine with GEDiCube (GEDiCube Press Release) (Renovaro Press Release) and to share our vision for the promising future of our newly combined company if you, as shareholders, approve the agreement. As we embark on this next chapter, we want to express our appreciation for your ongoing support and investment.

Renovaro Biosciences and GEDiCube strategically decided to combine our two companies just months ago. We believe the combination will accelerate our shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics.

The parties intend that I will serve as the CEO of the combined company. I am humbled and honored to serve in that role. I firmly believe that we will achieve far more together than either company could on its own. GEDiCube spent over a decade developing a proprietary AI platform that has already shown accuracy in detecting cancers earlier through analysis of complex molecular data. Renovaro leveraged decades of collective immunology expertise to develop a robust pipeline of novel immunotherapies.

By joining forces, our two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments. At the same time, we will maintain nimble independent operations, allowing each platform to advance rapidly.

I am excited to lead this combined company alongside our esteemed leadership team and board members, who offer unparalleled experience across AI, healthcare, and biotechnology. We share an ambitious vision to leverage AI to improve patient outcomes by detecting diseases sooner and matching treatments more precisely to the individual. We believe that the coming months will be exciting as we prepare to realize this combination's potential and deliver on our commitment to shareholders.

In this letter, I’d like to provide an update on the combined company, our shared vision, our plans for immediate revenue generation, and our opportunities.

Background
GEDiCube and Renovaro Biosciences came together through a shared desire to accelerate innovation in precision medicine. However, our crossing paths was not coincidental. It resulted from a carefully considered strategy to combine strengths and synergize work to elevate patient care by harnessing GEDiCube’s AI technology and its strategic partnerships, including with NVIDIA’s inception platform and Renovaro’s biotechnology.